HIMS is going to have a great 2026

AI Summary

Author argues HIMS is undervalued and set for a parabolic 2026 surge based on growth fundamentals, technical recovery pattern, high short interest, potential NVO partnership, and favorable peptide compounding regulatory rumors.

HIMS — LONG Author claims HIMS will potentially triple or more in 2026, arguing the stock has bottomed after a double bottom and has always recovered from prior 30%+ declines since 2022. The causal mechanism cited is a short squeeze setup with 67m short shares against a 184m float, plus catalysts from a potential NVO partnership and FDA/HHS peptide compounding rule changes that would benefit HIMS's unique peptide compounding facility. The specified horizon is 2026. The author states a position of 6,000 shares at $39.76.

I believe it is going to go PARABOLIC in 2026, and this is why:

Institutional Ownership - 239m shares. Shares outstanding - 228m Total float of shares - 184m TOTAL SHARES SHORT - 67m. this stock is ridiculously shorted, with 0 logic behind it, and it is setting up for a very easy parabolic move

Comments 5

▶ Full Post Text

I have been lurking in here for many years now, and I think its an extraordinary place to find undervalued stocks or great businesses overall, either to trade or to invest in.

I have seen it mentioned here before, but even then, maybe 1% of the amount of mentions it truly deserves.

this stock is HIMS.

I believe (my bad, I mean I KNOW), it is going to potentially triple, or even more, in 2026, and every person here should take a look at it.  
Lets look at the facts:

First of all, their financial statements

1. Revenue has been increasing for many years now, 148m in 2020 to 1.47b in 2024, and expected 2.25b in 2025. Projecting over 6.5b in 2030
2. Profitable and positive cash flow
3. healthy balance sheet
4. Buying back shares
5. Great Margins

Technicals:  
It has been on a long-term uptrend since may of 2022, with higher highs, and higher lows.  
during this time, it has had 10 declines of 30% or more (3 of them 50% or more, including the current one). EACH TIME it declined, it recovered either to an ATH or this year to the 65-70$ range.  
This year, it made its ATH in February at 73$, and it touched the 65-70$ range 4 times, which is now a major resistance range. currently, its at 33 dollars, which is its 3rd 50%+ decline, and 10th decline of 30% or more since may 2022. NOT BUYING right now, does not make ANY SENSE. its had a 100% success rate of recovering from each major decline the past 3.5 years, and now its no different.  
It has now made a double bottom, and its already at a pretty nice support level.  
I believe it has BOTTOMED.

Moreover, this year alone, they have announced LABS, Canada expansion, Europe expansion, some acquisitions, Testosterone treatments, and many more to come.

Now, just due to technicals its a very easy double from here, BUT, I believe it is going to go PARABOLIC in 2026, and this is why:

1. Institutional Ownership - 239m shares. Shares outstanding - 228m Total float of shares - 184m TOTAL SHARES SHORT - 67m. this stock is ridiculously shorted, with 0 logic behind it, and it is setting up for a very easy parabolic move
2. Potential NVO partnership, which is a major catalyst if it happens (and I think it will).
3. Rumors about the FDA & HHS revising the list of PEPTIDES allowed for compounding. HIMS is the only telehealth company in the US that has a peptide compounding facility. If this is true, ITS MASSIVE.

the potential catalysts + fundamentals + Technicals are saying 1 thing - the stock is going to have a great 2026, and im very shocked it is not the 1# mention here.

This is NOT FINANCIAL ADVICE, im just sharing my opinion.

my position - 6000 shares at 39.76$

▶ Full Post Text

Ideas

More from Reddit — r/investing